根據KPMG的研究顯示(2014)，生技製藥廠商間的合作是產業發展的趨勢，但合作的目的已經從原先的降低成本，發展到加速創新的產生。眾多國際製藥公司已經與外部夥伴進行合作，其中合作研發最能發揮合作夥伴間的效用，越緊密的合作越能使得合作網絡中多樣化的技術、能力結合，從而增強對於未被滿足醫療需求的理解。由此可見，跨國研發合作成為全球生技製藥廠商的企業策略。過去已有許多學者研究我國科技產業與國際廠商之研發合作，但甚少探究生技製藥廠商與國際生技製藥廠商間的研發合作。 本研究選定具有跨國研發合作豐富經驗的台灣生技製藥廠商為研究對象，探討其企業策略、核心能力及跨國研發動機如何影響跨國研發合作的管理。本研究從跨國研發合作影響因子以及跨國研發合作管理之內容兩個構面探討台灣生技製藥廠商與國際生技製藥廠商進行研發合作的互動關係。研究方法採取多重個案研究法，文獻探討部分包含生技製藥產業、企業策略與核心能力、國際研發合作、合作夥伴篩選因素、知識移轉與智財管理，研究者結合研究問題與文獻回顧導出觀念性研究架構，再依研究架構為主軸進行個案訪談與資料收集，實地深入訪談我國兩家生技製藥廠商，得出以下結論： 本研究發現，台灣生技製藥廠商與國際生技製藥廠商研進行發合作的動機一致，為降低及分散風險、分攤固定成本、技術與資源的互補與移轉、夥伴間營運策略的互補與相容性。篩選合作夥伴的主要考量也大致相同，包含資源及技術的互補、過往合作經驗、夥伴間營運策略的互補及相容性及財務能力。另外核心技術能力會影響台灣生技製藥廠商與合作夥伴合作起始的階段，研發合作起始階段的差異，更會影響知識移轉機制、以及合作方式的不同。另外，本研究也發現到，台灣生技製藥廠商在國際合作夥伴上的選擇會以不具直接競爭關係者為主，且與合作夥伴選擇以營業秘密的方式來保護技術知識。 / According to the research of KPMG in 2014, R&D collaboration between biopharmaceutical firms is the trend of biopharmaceutical industry. Under the circumstance of globalization, product life-cycles are gradually shortening. The purpose of R&D collaboration change from cost reduction to speeding up innovation. Therefore, multinational R&D collaboration has become a global business strategy for biopharmaceutical firms. Most of the past studies of multinational R&D collaboration focus on ICT industry in Taiwan. Few specially investigate biopharmaceutical industry. Consequently, a research gap can be found as multinational R&D collaborating between biopharmaceutical firms of Taiwan and biopharmaceutical firms of other countries. This research focus on the biopharmaceutical firms of Taiwan, explore how multinational R&D collaboration influence factors (business strategy, core competencies and the motivation of multinational R&D collaboration) affect multinational R&D collaboration management of firms. This research adopts two biopharmaceutical firms in Taiwan as case studies and conducts interviews with managers to understand multinational R&D collaboration influence factors and multinational R&D collaboration management. The conclusions of this research are as below: This research finds out that the motivations of multinational R&D collaboration of Taiwan firms are coincident, including cost reduction, diversification of risk, resources and technologies complementarity. The evaluations of partner selecting are also coincident, including resources and technologies complementarity, collaboration experience, operating strategy complementarity and financial capability. In addition, core competencies may affect the initiation stage of R&D collaboration and the initiation stage of R&D collaboration may affect the mechanisms of knowledge transfer and the way of multinational collaboration. Moreover, this research also found out that the biopharmaceutical firms of Taiwan might primarily choose to collaborate with international partners who have indirect competitive relationship with them. Last, the biopharmaceutical firms of Taiwan and their partners protect their intellectual property in the way of trade secret.